A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Novo Nordisk A/S

Participant type

Pediatric, Patients

Age range

0-17 years

Gender

Male and Female

Therapeutic area

Diseases [C] - Hemic and Lymphatic Diseases [C15]

Decision date (initial)

2026-02-06

Transition trial

No

Low-intervention

No

Rare-disease indication

Yes

Vulnerable population

Yes

External identifiers

EU CT number

2024-519881-32-00

ClinicalTrials.gov

NCT06198712

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Pharmacokinetic, Safety

• To assess the PK of etavopivat in patients with SCD • To assess the safety and tolerability of etavopivat during the 24-week primary treatment period.

Secondary objectives 5

1. To assess the safety and tolerability of etavopivat during the 72-week treatment extension period
2. To assess the effects of etavopivat on hemoglobin (Hb) response
3. To describe occurrence of vasoocclusive crisis (VOCs) in enrolled patients
4. To assess changes in fatigue of patients with SCD taking etavopivat
5. To assess changes in cerebral blood flow in patients with SCD taking etavopivat

Conditions and MedDRA coding

Sickle Cell Disease

Study design 4 periods

Regulatory references

EMA paediatric investigation plan (PIP)

EMEA-002924-PIP02-23

Plan to share IPD

No

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 8

1. 1. Patient’s parent, legal guardian, or legal representative has provided documented informed consent and patients have provided age-appropriate assent
2. 2. Age > 6 months and < 18 years of age at time of enrollment, according to the enrolling cohort:  Cohort 1: age 12 to < 18 years (adolescents)  Cohort 2: age 6 to < 12 years  Cohort 3: age 2 to < 6 years  Cohort 4: age 6 months to < 2 years
3. 3. Patient has confirmed diagnosis of SCD  Documentation of SCD genotype (HbSS, HbSβ0-thalassemia or other sickle cell syndrome variants) based on prior history of laboratory testing. Molecular genotyping is not required. SCD genotype may be determined from the results of Hb electrophoresis, high-performance liquid chromatography (HPLC), or similar testing. Note that Hb electrophoresis or HPLC is performed by the local laboratory at Screening.
4. 4. Hemoglobin ≥ 5.5 and < 10.5 g/dL
5. 5. Pediatric patients with severe SCD, as defined by at least 1 of the following:  2-15 episodes of documented VOC (defined in Section 8.4.2) within the 12 months prior to screening. Documentation must exist in the patient’s medical record prior to screening. Events based solely on patient recall without supporting documentation should not be counted towards eligibility.  Hospitalization for any SCD-related complication in the last 12 months prior to starting study treatment  Proteinuria, defined as an albumin:creatinine ratio (ACR) > 100 mg/g on 2 measures (separated by ≥ 1 month) as an indicator of early renal disease  History of a conditional TCD in the last 12 months prior to starting study treatment, but not currently being treated with chronic transfusion therapy (applicable to participants > 2 years of age). Conditional TCD is defined as a TAMMV of 170-199 cm/s by TCD or 155-184 cm/s by imaging TCD (TCDi).
6. 6. For participants taking HU, the dose of HU (mg/kg) must be stable (no more than a 20% change in dosing) for at least 90 days prior to start of study treatment with no anticipated need for dose adjustments during the study, in the opinion of the investigator
7. 7. Patients on crizanlizumab or L-glutamine treatment at the time of consent may be eligible if they:  Have been on a stable dose for ≥ 12 months at the time of consent (ie, no changes to the dose except for changes to weight or for safety reasons)  For patients on crizanlizumab, have been ≥ 80% compliant with the planned regimen during the 12 months prior to the time of consent
8. 8. Female patients of childbearing potential who are using acceptable methods of contraception and agree not to donate ova from study start to 90 days after the last dose of study drug, and male patients who are willing to use acceptable methods of contraception and agree not to donate sperm, from study start to 90 days after the last dose of study drug.

Exclusion criteria 10

1. 1. Female who is breastfeeding or pregnant
2. 2. More than 15 VOCs (as defined in Section 8.4.2) within the 12 months prior to starting study treatment that required a hospital, emergency room (ER), or clinic visit
3. 3. Hospitalized for sickle cell crisis or other vaso-occlusive event occurring in the 14 days prior to starting study treatment
4. 4. Abnormal TCD in the 12 months prior to starting study treatment
5. 5. Patients receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion)
6. 6. Received any blood products within 30 days of starting study treatment
7. 7. Receiving or use of concomitant medications that are strong inducers of cytochrome P450 (CYP) 3A4 within 2 weeks of starting study treatment
8. 8. Use of voxelotor within 28 days prior to starting study treatment or anticipated need for this agent during the study
9. 9. Receipt of erythropoietin or other hematopoietic growth factor treatment within 28 days of starting study treatment or anticipated need for such agents during the study
10. 10. Receipt of prior cellular based therapy (e.g., hematopoietic cell transplant, gene modification therapy)

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

1. • Single-dose: maximum concentration (Cmax), area under the concentration time curve (AUC)0-t, AUC0-inf • Steady-state etavopivat plasma exposure (Cmax,ss, AUCtau,ss, Cavg,ss, Cmin,ss) • Estimated using population PK • Incidence of AEs, SAEs, and AEs related to etavopivat • Number of premature discontinuations, dose interruptions, and dose reductions.

Secondary endpoints 5

1. • Incidence of AEs, SAEs, and AEs related to etavopivat (extension period) • Number of premature discontinuations, dose interruptions, and dose reductions (extension period)
2. • Hb response rate at Weeks 12 and 24 (increase of > 1 g/dL from baseline) • Change in Hb from baseline at Weeks 12 and 24
3. Incidence of VOCs during the 24-week primary treatment period o Number of VOCs o Annualized Rate of VOC
4. Change from baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale at Weeks 12 and 24 (between 5 to 18 years of age)
5. Change from baseline in time-averaged mean of the maximum velocity (TAMMV) by transcranial Doppler ultrasonography (TCD) (> 2 years of age)

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 2

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Novo Nordisk A/S

Sponsor organisation

Novo Nordisk A/S

Address

Novo Alle 1

City

Bagsvaerd

Postcode

2880

Country

Denmark

Scientific contact point

Organisation

Novo Nordisk A/S

Contact name

Sunil Navani

Public contact point

Organisation

Novo Nordisk A/S

Contact name

EU Submission Hub

Third parties 12

Sponsor responsibilities

Article 77 compliance

Novo Nordisk A/S

Contact point sponsor

Novo Nordisk A/S

Article 77 implementation

Novo Nordisk A/S

Locations

1 EU/EEA country · 3 investigational sites

By country

Investigational sites

Application history

3 submissions — initial application plus substantial / non-substantial modifications